Cenduit to Showcase Quantum Interactive at DIA China 2017

DURHAM, NC, UNITED STATES - May 16, 2017 -  

WHAT:              Cenduit, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is showcasing its solutions and expertise as the largest interactive response technology (IRT) specialist in the world at DIA China, May 21-24 in Shanghai, China.

During the show, Cenduit will demonstrate its newest rapid study build software, Quantum Interactive™, for attendees. This new design tool increases IRT quality, resulting in the creation of a functioning prototype of an initial study build within minutes.

Attendees are invited to stop by Cenduit’s booth #H02 to see the new study builder and learn how the company’s IRT solutions can help sponsors increase efficiencies and quality delivery, saving study teams time and resources. 
 

WHO:             Joe Zhou, Business Development Executive

                      David Horsley, Head of Asia Business Development

                      Anant Dhume, Associate Product Manager

WHEN:           Sunday, May 21 - Wednesday, May 24, 2017

WHERE:        Shanghai International Convention Center

                     No. 2727, Riverside Avenue

                     Pudong

                     200120 Shanghai, China
 

DETAILS:      For media inquiries, please contact Greyson Feurer at Largemouth Communications, (919) 459-6460, greyson@largemouthpr.com.
 

ABOUT:         Cenduit, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is the largest IRT specialist in the world with the expertise to empower sponsors for success by implementing a completely personalized system that puts them in control of their clinical trials. With the needs of investigator sites and patients top of mind, Cenduit offers clinical supply chain intelligence and clinical operations know-how through its IRT-driven services: patient randomization, patient reminders, drug supply management, and eClinical integration. Incorporated in 2007, Cenduit and has offices in the US, UK, Switzerland, India, and Japan, and global clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. For additional information, visit Cenduit online at www.cenduit.com; on Twitter @CenduitLLC or on LinkedIn at www.LinkedIn.com/Company/Cenduit.

###